Genecentric Therapeutics, Inc. is a biotechnology company based in Research Triangle Park, NC, specializing in the development of precision medicine solutions for cancer treatment. The company focuses on leveraging advanced genomic technologies to identify and validate biomarkers that can guide therapeutic decisions. By integrating data-driven insights with innovative research methodologies, Genecentric aims to enhance patient outcomes and streamline the drug development process in oncology, contributing to the evolving landscape of personalized healthcare.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

10 Patents

#29 in Research Triangle Park, NC

#619 in North Carolina

#29,866 in US

#56,047 in the World

Research Triangle Park, NC, United States of America

Genecentric Therapeutics, Inc.

Forward Citations = 13

12 inventors:

Charles M Perou (10 out of 19 patents)

Hawazin Faruki (9 out of 9 patents)

Myla Lai-Goldman (9 out of 9 patents)

4. Greg Mayhew (8 out of 8 patents)

5. David Neil Hayes (7 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Genecentric Therapeutics, Inc.. Retrieved from https://idiyas.com/company/genecentric-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

3 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]